Spots Global Cancer Trial Database for VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Official Title: An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery

Study ID: NCT03750071

Conditions

Recurrent Glioblastoma

Interventions

VXM01

Avelumab

Study Description

Brief Summary: VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery

Detailed Description: The trial is conducted as a multicenter, open-label, Phase I/II trial to evaluate the efficacy and safety of VXM01 in combination with avelumab in subjects with resectable and non-resectable progressive glioblastoma following tumor resection and radiochemotherapy containing temozolomide. The trial will be performed in 30 subjects with progressive glioblastoma: * 24 subjects who will not be candidates for a tumor re-operation (non-resectable subjects) * 6 subjects who will be candidates for a tumor re-operation (resectable subjects) The trial, for each subject, will consist of a screening period, a treatment and observatioon phase of 60 weeks including, a treatment phase of up to 48 weeks with prime and boosting administrations of VXM01 in combination with avelumab and an observation phase of 12 weeks and with an end of trial visit at Week 60. Subjects will receive VXM01 in combination with avelumab up to Week 48. The end of study (EoS) visit assessments will be performed Week 60.